Post-transcriptional Regulation by Cytosine-5 Methylation of RNA
Overview
Biophysics
Genetics
Molecular Biology
Affiliations
The recent advent of high-throughput sequencing technologies coupled with RNA modifications detection methods has allowed the detection of RNA modifications at single nucleotide resolution giving a more comprehensive landscape of post-transcriptional gene regulation pathways. In this review, we focus on the occurrence of 5-methylcytosine (mC) in the transcriptome. We summarise the main findings of the molecular role in post-transcriptional regulation that governs mC deposition in RNAs. Functionally, mC deposition can regulate several cellular and physiological processes including development, differentiation and survival to stress stimuli. Despite many aspects concerning mC deposition in RNA, such as position or sequence context and the fact that many readers and erasers still remain elusive, the overall recent findings indicate that RNA cytosine methylation is a powerful mechanism to post-transcriptionally regulate physiological processes. In addition, mutations in RNA cytosine-5 methyltransferases are associated to pathological processes ranging from neurological syndromes to cancer.
NSUN7 promotes cervical cancer progression through activation of ErbB signaling pathway.
Li Y, Lu R, Abuduhailili X, Feng Y Funct Integr Genomics. 2025; 25(1):37.
PMID: 39954044 DOI: 10.1007/s10142-025-01546-9.
Meng S, Yang G, Yu E, Li J Front Immunol. 2024; 15:1477828.
PMID: 39726589 PMC: 11669668. DOI: 10.3389/fimmu.2024.1477828.
Narrative review of research progress of RNA mC methylation in head and neck malignancies.
Cheng L, Wang C, Zhao D, Wu S Transl Cancer Res. 2024; 13(9):5112-5122.
PMID: 39430837 PMC: 11483327. DOI: 10.21037/tcr-24-103.
Regulations of mA and other RNA modifications and their roles in cancer.
Chen X, Guo K, Li J, Xu S, Zhu H, Yan G Front Med. 2024; 18(4):622-648.
PMID: 38907157 DOI: 10.1007/s11684-024-1064-8.
The role of RNA methylation in tumor immunity and its potential in immunotherapy.
Li Y, Jin H, Li Q, Shi L, Mao Y, Zhao L Mol Cancer. 2024; 23(1):130.
PMID: 38902779 PMC: 11188252. DOI: 10.1186/s12943-024-02041-8.